Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MS1819-SD plus porcine pancreatic extracts in cystic fibrosis patients with severe exocrine pancreatic insufficiency
2018-003831-31Phase 2Completed
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Oct 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF), sponsored by Entero Therapeutics, Inc. Primary endpoint: Coefficient of fat absorption (CFA). Started Oct 2018; status: completed.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-003831-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003831-31.